RUNX2 and Hyperglycemia: In light of these findings, glabridin, which also exhibits estrogenic activity [25] and has also been reported to modulate β-catenin, Runx-2, and osteocalcin expression [15,26], could prevent hyperglycemia-induced bone loss through the same mechanism as naringenin and genistein.